Monitor for initiation of the Peeling Skin Syndrome clinical trial before year-end and any subsequent data readouts. The orphan drug designation is a positive regulatory signal but does not change the pre-revenue status or near-term cash runway.
Price Chart
Executive Summary
Quoin Pharmaceuticals announced that its lead product candidate QRX003 received Orphan Drug Designation from the EMA for Peeling Skin Syndrome, providing 10 years of market exclusivity in Europe upon approval. The company also stated it is on track to initiate the first-ever formal clinical trial for Peeling Skin Syndrome before year-end. This is a regulatory milestone for a pre-revenue biotech with no financial data in the filing.
Key Facts
- QRX003 granted Orphan Drug Designation in Europe by EMA for Peeling Skin Syndrome
- If approved, QRX003 will receive 10 years of market exclusivity in Europe for Peeling Skin Syndrome
- Company intends to initiate first-ever formal clinical study for Peeling Skin Syndrome before year-end
- QRX003 has now received eight regulatory milestones across both Netherton Syndrome and Peeling Skin Syndrome indications
- QRX003 also has Orphan Drug Designation in US, Europe, and Japan for Netherton Syndrome
Financial Impact
No financial data provided in filing; no revenue, cash runway, or deal values disclosed
Risk Factors
- Clinical trial failure in Peeling Skin Syndrome or Netherton Syndrome trials
- Regulatory approval not guaranteed despite orphan designation
- Pre-revenue company with no disclosed cash runway in this filing
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-115709 |
| Document: tm2627548d1_ex99-1.htm | 0001104659-26-115709 |
| Document: 0001104659-26-115709-index-headers.html | 0001104659-26-115709 |
| Document: 0001104659-26-115709-index.html | 0001104659-26-115709 |
| Document: 0001104659-26-115709.txt | 0001104659-26-115709 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | 8-K | $4.04 | awaiting T+5 | — | $4.01 (−0.74%) |
Oct 19, 2026 7d ago | ANALYST-UPGRADE | $3.98 $4.01 | ▲ +0.75% | ▲ +0.90% | $4.01 (+0.75%) |
Oct 14, 2026 12d ago | 8-K | $4.10 $3.99 | ▼ −2.68% | ▼ −3.14% | $4.01 (−2.20%) |
Oct 12, 2026 14d ago | ANALYST-UPGRADE | $4.36 $3.98 | ▼ −8.72% | ▼ −6.81% | $4.01 (−8.03%) |
Oct 7, 2026 19d ago | SC 13G/A | $4.55 $4.03 | ▲ +11.43% | ▲ +11.15% | $4.01 (+11.87%) |
Oct 2, 2026 24d ago | DEF 14A | $4.56 $4.36 | ▼ −4.28% | ▼ −4.70% | $4.01 (−11.96%) |
Sep 28, 2026 28d ago | EFFECT | $5.26 $4.56 | ▲ +13.40% | ▲ +14.61% | $4.01 (+23.76%) |
Sep 22, 2026 4w ago | Press Release | $7.01 $4.88 | ▼ −30.39% | ▼ −29.20% | $4.01 (−42.80%) |
Sep 18, 2026 5w ago | S-3 | $6.90 $5.26 | ▲ +23.77% | ▲ +22.75% | $4.01 (+41.88%) |
Sep 1, 2026 7w ago | Insider Cluster | $6.74 $6.90 | ▲ +2.37% | ▲ +3.33% | $4.01 (−40.50%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers